Endocyte Inc plans to issue shares of its common stock through an underwritten registered public offering.
Underwriters will have a 30-day option to buy an additional 15% of shares.
Go deeper with GlobalData
The US-based biopharmaceutical company will use proceeds for the clinical development of its pipeline products and for general corporate purposes.
The company has appointed Jefferies LLC, Wells Fargo Securities LLC, and Deutsche Bank Securities Inc as joint book-running managers for the transaction.
vTv Therapeutics Inc plans to issue class A common stock shares in a public offering to raise $250m.
The US-based pharmaceutical company plans to use proceeds towards general corporate needs.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataPaul, Weiss, Rifkind, Wharton & Garrison LLP has been appointed as the legal adviser for the transaction.
Prothena Corp Plc has filed a registration statement with the US Securities and Exchange Commission (SEC) for a public offering of shares.
The Ireland-based biotechnology company has appointed A&L Goodbody as the legal advisor for the transaction.
Tyme Technologies Inc has issued 12 million shares of its common stock in an underwritten public offering.
Underwriters will have a 30-day option to buy an additional 1.8 million shares.
The US-based clinical-stage pharmaceutical company plans to use the proceeds towards research and development of its SM-88 product and general corporate needs.
The company has selected Evercore Group LLC, Stifel, Nicolaus & Company, Incorporated and Canaccord Genuity Inc as the joint book-running managers for the deal.
Amarantus Bioscience Holdings Inc has issued 12% series I convertible preferred stock in a private placement to raise $1.5m.
Institutional investors will subscribe to the placement.
The US-based biotechnology company will raise $1.5m in five tranches of $300,000 each. The investors will receive 300 shares of 12% series I convertible preferred stock at $1,000 a share for each tranche.
Amarantus has appointed Dominick & Dickerman LLC and Paulson Investment Company Inc as co-placement agents for the transaction.
Prokarium Ltd has raised $10m in a financing round led by Riyadh Valley Company.
Flerie Invest AB and Korea Investment Partners (KIP) also participated in the funding round.
The UK-based biotechnology company plans to use funds for the clinical development of new vaccines against Chlamydia, C.difficile and enteric fever, as well as for the expansion of its immuno-oncology research and development (R&D) team.
Belgium-based biopharmaceutical company Asit Biotech SA has issued 543,556 new shares priced at €3.83 ($4.71) a share in the second tranche of a private placement to raise €2.1m ($2.58m).
Asit Biotech has simultaneously issued 626,146 shares to raise €2.4m ($2.95m) in a private placement.
Okogen Inc has secured A$13m ($10.17m) through a series A financing round led by Medical Research Commercialisation Fund (MRCF) by Brandon Capital.
The US-based ophthalmic anti-infective drugs developer plans to use proceeds towards the development of its lead ophthalmic formulation candidate OKG-0301.
